Cantargia secures exercise of warrants of series TO 1

Cantargia AB (“Cantargia”) announces that the company has obtained prior confirmation of the exercise of 100 per cent of all warrants of series TO 1.

There are 592,098 outstanding warrants of series TO 1, which were issued in connection with an offset issue in October 2014 and which are exercisable during the period 23 March – 13 April 2016. The company has secured subscriptions and payment for 100 per cent of all warrants of series TO 1 in advance. This means that Cantargia will raise approximately SEK 4.5 million before issue costs.

“The fact that we were able to obtain prior confirmation of the exercise of the warrants shows that Cantargia has investors who really believe in the company. The capital injection will contribute to our ongoing preparations for the clinical phase I/IIa study that we are planning to initiate towards the end of the year”, CEO Göran Forsberg, says.

There are also 4,350,000 outstanding warrants of series TO3, which are traded on Nasdaq First North Stockholm. The exercise period for warrants of series TO 3 is the same as for warrants of series TO 1, i.e. 23 March – 13 April 2016. Holders of warrants are entitled, for each warrant, to subscribe for one new share of Cantargia at a subscription price of SEK 7.60 per share. If all warrants of series TO 3 are exercised Cantargia would raise approximately SEK 33.1 million before issue costs.

There are also outstanding warrants of series TO 2 and TO 4, for which the exercise period falls in autumn 2016.

For further information, please contact
Göran Forsberg, CEO
Telephone: 046 275 62 60
E-mail: goran.forsberg@cantargia.com

wkr0006.pdf